I do believe that invasive lobular breast cancer is a completely different entity. So it’s not the same and we should not extrapolate endpoints from the other trials and the other large enrolling trials to the lobular. So we are trying to pass the message that we should do trials focusing on this subtype and we’ve seen several subgroup analyses show that it’s a different entity...
I do believe that invasive lobular breast cancer is a completely different entity. So it’s not the same and we should not extrapolate endpoints from the other trials and the other large enrolling trials to the lobular. So we are trying to pass the message that we should do trials focusing on this subtype and we’ve seen several subgroup analyses show that it’s a different entity. But we want trials powered to assess the efficacy in lobular. So I do believe that we should focus on trials designed with lobular being the subtype of focus. And the endpoint, we’ve been saying that, it’s not the same. So overall response rate, in the early setting, I think it’s a good endpoint for this case.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
